Chemotherapy-induced nausea and vomiting in Italian cancer centers: Results of CINVDAY, a prospective, multicenter study

Michele De Tursi, Consiglia Carella, Silverio Tomao, Saverio Cinieri, Vito Lorusso, Paolo Marchetti, Stefania Vecchio, Elisabetta Sansoni, Antonio Contu, Vincenzo Adamo, Nicola Silvestris, Antonio Nuzzo, Giovanni Rosti, Alberto Ravaioli, Marco Danova, Giuseppe Tonini, Rodolfo Passalacqua, Giorgio Cruciani, Marina Faedi, Massimiliano SpadaMichelino De Laurentiis, Domenico Amoroso, Federica Tomao, Isabella Sperduti, Antonino Grassadonia, Nicola Tinari, Clara Natoli, Stefano Iacobelli

Research output: Contribution to journalArticle

Abstract

Purpose. Guideline consistency in the prevention of chemotherapy-induced nausea and vomiting (CINV) remains low (29% in the Pan European Emesis Registry study) and very low (11%) in regimens with a high emetogenic risk. The aim of this study was to evaluate the guideline consistency of CINV prophylaxis for acute emesis in daily clinical practice in Italy. Methods. This was a prospective, observational, multicenter study. Patients scheduled to receive antitumor treatment on a single prespecified day were included. Data on patient characteristics (demographic and clinical), type of anticancer therapy, and type of antiemetic therapy prescribed for acute emesis were collected on electronic data capture forms. Chemotherapy regimens and antiemetic prophylaxis were categorized according to the MASCC 2011 guidelines. The study was approved by the local ethics committees. Results. From July 2013 to February 2014, a total of 502 patients were enrolled at 26 study sites. Median age was 62 years (range 27-87 years). Colorectal cancer and breast cancer were the most common malignancies. The emetogenic potential of the chemotherapy regimens used was high (HEC) (23.7%), moderate (MEC) (40.6%), low (31.3%) or minimal (4.4%). Overall, guideline consistency was 19.3%. Consistency reached 45% when the various 5HT3 receptor antagonists were considered equivalent and interchangeable in MEC regimens. Adherence to guidelines was lowest for MEC and MINIMAL risk groups. Ten percent of patients in HEC and MEC regimens did not receive any 5HT3 receptor antagonists. NK1 receptor antagonists were used in 8% of all regimens. Conclusions. Our study indicates that antiemetic guideline inconsistency remains an issue in daily clinical oncology practice in Italy.

Original languageEnglish
Pages (from-to)e309-e313
JournalTumori
Volume100
Issue number6
DOIs
Publication statusPublished - Nov 1 2014

Fingerprint

Nausea
Multicenter Studies
Vomiting
Antiemetics
Prospective Studies
Guidelines
Drug Therapy
Neoplasms
Italy
Breast Neoplasms
Guideline Adherence
Ethics Committees
Medical Oncology
Observational Studies
Registries
Colorectal Neoplasms
Therapeutics
Demography
MEC regimen

Keywords

  • Antiemetic therapy
  • CINV
  • Emesis
  • Guidelines adherence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Chemotherapy-induced nausea and vomiting in Italian cancer centers : Results of CINVDAY, a prospective, multicenter study. / De Tursi, Michele; Carella, Consiglia; Tomao, Silverio; Cinieri, Saverio; Lorusso, Vito; Marchetti, Paolo; Vecchio, Stefania; Sansoni, Elisabetta; Contu, Antonio; Adamo, Vincenzo; Silvestris, Nicola; Nuzzo, Antonio; Rosti, Giovanni; Ravaioli, Alberto; Danova, Marco; Tonini, Giuseppe; Passalacqua, Rodolfo; Cruciani, Giorgio; Faedi, Marina; Spada, Massimiliano; De Laurentiis, Michelino; Amoroso, Domenico; Tomao, Federica; Sperduti, Isabella; Grassadonia, Antonino; Tinari, Nicola; Natoli, Clara; Iacobelli, Stefano.

In: Tumori, Vol. 100, No. 6, 01.11.2014, p. e309-e313.

Research output: Contribution to journalArticle

De Tursi, M, Carella, C, Tomao, S, Cinieri, S, Lorusso, V, Marchetti, P, Vecchio, S, Sansoni, E, Contu, A, Adamo, V, Silvestris, N, Nuzzo, A, Rosti, G, Ravaioli, A, Danova, M, Tonini, G, Passalacqua, R, Cruciani, G, Faedi, M, Spada, M, De Laurentiis, M, Amoroso, D, Tomao, F, Sperduti, I, Grassadonia, A, Tinari, N, Natoli, C & Iacobelli, S 2014, 'Chemotherapy-induced nausea and vomiting in Italian cancer centers: Results of CINVDAY, a prospective, multicenter study', Tumori, vol. 100, no. 6, pp. e309-e313. https://doi.org/10.1700/1778.19310
De Tursi, Michele ; Carella, Consiglia ; Tomao, Silverio ; Cinieri, Saverio ; Lorusso, Vito ; Marchetti, Paolo ; Vecchio, Stefania ; Sansoni, Elisabetta ; Contu, Antonio ; Adamo, Vincenzo ; Silvestris, Nicola ; Nuzzo, Antonio ; Rosti, Giovanni ; Ravaioli, Alberto ; Danova, Marco ; Tonini, Giuseppe ; Passalacqua, Rodolfo ; Cruciani, Giorgio ; Faedi, Marina ; Spada, Massimiliano ; De Laurentiis, Michelino ; Amoroso, Domenico ; Tomao, Federica ; Sperduti, Isabella ; Grassadonia, Antonino ; Tinari, Nicola ; Natoli, Clara ; Iacobelli, Stefano. / Chemotherapy-induced nausea and vomiting in Italian cancer centers : Results of CINVDAY, a prospective, multicenter study. In: Tumori. 2014 ; Vol. 100, No. 6. pp. e309-e313.
@article{c231f589e5e94e2a91e5776a81cb0289,
title = "Chemotherapy-induced nausea and vomiting in Italian cancer centers: Results of CINVDAY, a prospective, multicenter study",
abstract = "Purpose. Guideline consistency in the prevention of chemotherapy-induced nausea and vomiting (CINV) remains low (29{\%} in the Pan European Emesis Registry study) and very low (11{\%}) in regimens with a high emetogenic risk. The aim of this study was to evaluate the guideline consistency of CINV prophylaxis for acute emesis in daily clinical practice in Italy. Methods. This was a prospective, observational, multicenter study. Patients scheduled to receive antitumor treatment on a single prespecified day were included. Data on patient characteristics (demographic and clinical), type of anticancer therapy, and type of antiemetic therapy prescribed for acute emesis were collected on electronic data capture forms. Chemotherapy regimens and antiemetic prophylaxis were categorized according to the MASCC 2011 guidelines. The study was approved by the local ethics committees. Results. From July 2013 to February 2014, a total of 502 patients were enrolled at 26 study sites. Median age was 62 years (range 27-87 years). Colorectal cancer and breast cancer were the most common malignancies. The emetogenic potential of the chemotherapy regimens used was high (HEC) (23.7{\%}), moderate (MEC) (40.6{\%}), low (31.3{\%}) or minimal (4.4{\%}). Overall, guideline consistency was 19.3{\%}. Consistency reached 45{\%} when the various 5HT3 receptor antagonists were considered equivalent and interchangeable in MEC regimens. Adherence to guidelines was lowest for MEC and MINIMAL risk groups. Ten percent of patients in HEC and MEC regimens did not receive any 5HT3 receptor antagonists. NK1 receptor antagonists were used in 8{\%} of all regimens. Conclusions. Our study indicates that antiemetic guideline inconsistency remains an issue in daily clinical oncology practice in Italy.",
keywords = "Antiemetic therapy, CINV, Emesis, Guidelines adherence",
author = "{De Tursi}, Michele and Consiglia Carella and Silverio Tomao and Saverio Cinieri and Vito Lorusso and Paolo Marchetti and Stefania Vecchio and Elisabetta Sansoni and Antonio Contu and Vincenzo Adamo and Nicola Silvestris and Antonio Nuzzo and Giovanni Rosti and Alberto Ravaioli and Marco Danova and Giuseppe Tonini and Rodolfo Passalacqua and Giorgio Cruciani and Marina Faedi and Massimiliano Spada and {De Laurentiis}, Michelino and Domenico Amoroso and Federica Tomao and Isabella Sperduti and Antonino Grassadonia and Nicola Tinari and Clara Natoli and Stefano Iacobelli",
year = "2014",
month = "11",
day = "1",
doi = "10.1700/1778.19310",
language = "English",
volume = "100",
pages = "e309--e313",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Chemotherapy-induced nausea and vomiting in Italian cancer centers

T2 - Results of CINVDAY, a prospective, multicenter study

AU - De Tursi, Michele

AU - Carella, Consiglia

AU - Tomao, Silverio

AU - Cinieri, Saverio

AU - Lorusso, Vito

AU - Marchetti, Paolo

AU - Vecchio, Stefania

AU - Sansoni, Elisabetta

AU - Contu, Antonio

AU - Adamo, Vincenzo

AU - Silvestris, Nicola

AU - Nuzzo, Antonio

AU - Rosti, Giovanni

AU - Ravaioli, Alberto

AU - Danova, Marco

AU - Tonini, Giuseppe

AU - Passalacqua, Rodolfo

AU - Cruciani, Giorgio

AU - Faedi, Marina

AU - Spada, Massimiliano

AU - De Laurentiis, Michelino

AU - Amoroso, Domenico

AU - Tomao, Federica

AU - Sperduti, Isabella

AU - Grassadonia, Antonino

AU - Tinari, Nicola

AU - Natoli, Clara

AU - Iacobelli, Stefano

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Purpose. Guideline consistency in the prevention of chemotherapy-induced nausea and vomiting (CINV) remains low (29% in the Pan European Emesis Registry study) and very low (11%) in regimens with a high emetogenic risk. The aim of this study was to evaluate the guideline consistency of CINV prophylaxis for acute emesis in daily clinical practice in Italy. Methods. This was a prospective, observational, multicenter study. Patients scheduled to receive antitumor treatment on a single prespecified day were included. Data on patient characteristics (demographic and clinical), type of anticancer therapy, and type of antiemetic therapy prescribed for acute emesis were collected on electronic data capture forms. Chemotherapy regimens and antiemetic prophylaxis were categorized according to the MASCC 2011 guidelines. The study was approved by the local ethics committees. Results. From July 2013 to February 2014, a total of 502 patients were enrolled at 26 study sites. Median age was 62 years (range 27-87 years). Colorectal cancer and breast cancer were the most common malignancies. The emetogenic potential of the chemotherapy regimens used was high (HEC) (23.7%), moderate (MEC) (40.6%), low (31.3%) or minimal (4.4%). Overall, guideline consistency was 19.3%. Consistency reached 45% when the various 5HT3 receptor antagonists were considered equivalent and interchangeable in MEC regimens. Adherence to guidelines was lowest for MEC and MINIMAL risk groups. Ten percent of patients in HEC and MEC regimens did not receive any 5HT3 receptor antagonists. NK1 receptor antagonists were used in 8% of all regimens. Conclusions. Our study indicates that antiemetic guideline inconsistency remains an issue in daily clinical oncology practice in Italy.

AB - Purpose. Guideline consistency in the prevention of chemotherapy-induced nausea and vomiting (CINV) remains low (29% in the Pan European Emesis Registry study) and very low (11%) in regimens with a high emetogenic risk. The aim of this study was to evaluate the guideline consistency of CINV prophylaxis for acute emesis in daily clinical practice in Italy. Methods. This was a prospective, observational, multicenter study. Patients scheduled to receive antitumor treatment on a single prespecified day were included. Data on patient characteristics (demographic and clinical), type of anticancer therapy, and type of antiemetic therapy prescribed for acute emesis were collected on electronic data capture forms. Chemotherapy regimens and antiemetic prophylaxis were categorized according to the MASCC 2011 guidelines. The study was approved by the local ethics committees. Results. From July 2013 to February 2014, a total of 502 patients were enrolled at 26 study sites. Median age was 62 years (range 27-87 years). Colorectal cancer and breast cancer were the most common malignancies. The emetogenic potential of the chemotherapy regimens used was high (HEC) (23.7%), moderate (MEC) (40.6%), low (31.3%) or minimal (4.4%). Overall, guideline consistency was 19.3%. Consistency reached 45% when the various 5HT3 receptor antagonists were considered equivalent and interchangeable in MEC regimens. Adherence to guidelines was lowest for MEC and MINIMAL risk groups. Ten percent of patients in HEC and MEC regimens did not receive any 5HT3 receptor antagonists. NK1 receptor antagonists were used in 8% of all regimens. Conclusions. Our study indicates that antiemetic guideline inconsistency remains an issue in daily clinical oncology practice in Italy.

KW - Antiemetic therapy

KW - CINV

KW - Emesis

KW - Guidelines adherence

UR - http://www.scopus.com/inward/record.url?scp=84923285004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923285004&partnerID=8YFLogxK

U2 - 10.1700/1778.19310

DO - 10.1700/1778.19310

M3 - Article

C2 - 25688518

AN - SCOPUS:84923285004

VL - 100

SP - e309-e313

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 6

ER -